Senator questions penalty for vaccine data fraud; Japan readies for latest measles outbreak;

> Senator Chuck Grassley has questioned why the researcher who falsified AIDS vaccine data wasn't given a tougher penalty. News

> A jump in measles cases in Japan has raised fears the undervaccinated country faces another outbreak. Article

> Novartis ($NVS) is aiming to wrap up a strategic review of its underperforming vaccine unit by mid-year. Report

> John Hopkins researchers have developed an app to help hospitals forecast numbers of flu patients. Post

> Croatia's Institute of Immunology faces an uncertain future after losing key production licenses. Piece

> Research suggests vaccinating elder siblings against respiratory syncytial virus could stop babies from getting ill. Item

> Sinovac Biotech has applied to test its H7N9 vaccine in a clinical trial in China. Report

> iBio has begun a Phase I trial of its green plant-produced malaria vaccine. Release

> Sanofi-owned Shantha Biotechnics is developing polio vaccines. Article

> Canadian authorities have reassured the public about the effectiveness of the measles vaccine after three people fell ill despite being immunized. News

> The co-founder of Oracle ($ORCL) is to donate $100 million through his foundation to help eradicate polio. Item

> An outbreak of whooping cough has hit an Amish community in Delaware. Piece

Suggested Articles

Novavax will have billions of doses of COVID-19 vaccine capacity next year and could single-handedly meet U.S. demand, executives said.

As top players race to deliver COVID-19 vaccines, Russia approved a locally developed shot based on skimpy data. Experts called it a political stunt.

Already developing coronavirus treatments, Takeda struck a licensing deal to manufacture and market Novavax's vaccine candidate in Japan